NICE-SUGAR Trial: 2009, Intensive versus Conventional Glucose Control in Critically Ill Patients | NEJM
The NICE trial tackled an important question of what should be the goal blood glucose levels in critically ill patients. The results of this trial were quiet significant and showed tighter or intensive blood glucose control was associated with highter 28 days and 90 days mortality. Additionally, it also led to an increase number of hypoglycemic episodes in these patients.
Guideline recommendations based on NICE-SUGAR Trial
The American Diabetes Association recommends starting insulin in patients with persistent hyperglycemia above 180 mg/dL in critically ill patients, and to maintain the glycemic range between 140-180 mg/dL.